Jasper Therapeutics, Inc.
JSPR
$5.41
$0.030.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.72% | 20.38% | 3.69% | 15.26% | -12.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.65% | 2.72% | -10.29% | 8.07% | 28.94% |
| Operating Income | -42.65% | -2.72% | 10.29% | -8.07% | -28.94% |
| Income Before Tax | -46.68% | -6.23% | 9.31% | 3.73% | -25.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.68% | -6.23% | 9.31% | 3.73% | -25.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.68% | -6.23% | 9.31% | 3.73% | -25.51% |
| EBIT | -42.65% | -2.72% | 10.29% | -8.07% | -28.94% |
| EBITDA | -43.56% | -1.37% | 10.59% | -8.13% | -29.45% |
| EPS Basic | -7.94% | 22.30% | 33.91% | 36.56% | 58.35% |
| Normalized Basic EPS | -7.76% | 23.67% | 35.59% | 33.07% | 58.54% |
| EPS Diluted | -7.94% | 22.30% | 33.91% | 36.56% | 58.35% |
| Normalized Diluted EPS | -7.76% | 23.67% | 35.59% | 33.07% | 58.54% |
| Average Basic Shares Outstanding | 35.89% | 36.72% | 37.22% | 51.74% | 201.33% |
| Average Diluted Shares Outstanding | 35.89% | 36.72% | 37.22% | 51.74% | 201.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |